CN115397411A - 药物组合及其用途 - Google Patents

药物组合及其用途 Download PDF

Info

Publication number
CN115397411A
CN115397411A CN202180027954.XA CN202180027954A CN115397411A CN 115397411 A CN115397411 A CN 115397411A CN 202180027954 A CN202180027954 A CN 202180027954A CN 115397411 A CN115397411 A CN 115397411A
Authority
CN
China
Prior art keywords
derivative
ascorbic acid
inhibitor
platinum
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180027954.XA
Other languages
English (en)
Inventor
许诺
林坚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Yangshengtang Institute of Natural Medication Co Ltd
Original Assignee
Zhejiang Yangshengtang Institute of Natural Medication Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Yangshengtang Institute of Natural Medication Co Ltd filed Critical Zhejiang Yangshengtang Institute of Natural Medication Co Ltd
Publication of CN115397411A publication Critical patent/CN115397411A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种用于预防和/或***的药物组合，其包含：a)预防和/或治疗有效量的抗坏血酸或其衍生物；以及b)预防和/或治疗有效量的PDE4选择性抑制剂。

Description

PCT国内申请，说明书已公开。

Claims (73)

  1. PCT国内申请，权利要求书已公开。
CN202180027954.XA 2020-04-23 2021-04-22 药物组合及其用途 Pending CN115397411A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010329182 2020-04-23
CN2020103291822 2020-04-23
PCT/CN2021/088840 WO2021213455A1 (zh) 2020-04-23 2021-04-22 药物组合及其用途

Publications (1)

Publication Number Publication Date
CN115397411A true CN115397411A (zh) 2022-11-25

Family

ID=78270282

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180027954.XA Pending CN115397411A (zh) 2020-04-23 2021-04-22 药物组合及其用途

Country Status (4)

Country Link
US (1) US20230338345A1 (zh)
EP (1) EP4140480A4 (zh)
CN (1) CN115397411A (zh)
WO (1) WO2021213455A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282413A1 (en) * 2021-01-21 2023-11-29 Natural Medicine Institute Of Zhejiang Yangshengtang Co., Ltd. Composition and method for treating tumors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0398484T3 (da) 1989-05-19 1995-07-24 Hayashibara Biochem Lab Alpha-Glycosyl-L-ascorbinsyre, fremstilling og anvendelser heraf
US5078989A (en) 1990-03-28 1992-01-07 Sunstar K.K. Skin whitening cosmetics
CN1046939C (zh) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
HU225779B1 (en) * 1999-07-28 2007-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
WO2003057707A1 (en) 2001-12-28 2003-07-17 Suntory Limited 2-o-( -d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it
WO2006094640A2 (en) * 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
WO2006110588A2 (en) * 2005-04-11 2006-10-19 The Trustees Of Columbia University In The City Of New York Methods for treating mild cognitive impairment
KR20080005601A (ko) * 2005-05-11 2008-01-14 니코메드 게엠베하 Ｐｄｅ４ 억제제 로플루밀라스트와 테트라히드로비오프테린유도체의 조합
WO2013188138A1 (en) * 2012-06-11 2013-12-19 The Regents Of The University Of California Inhibitors of hippo-yap signaling pathway
KR101661898B1 (ko) * 2014-02-11 2016-10-04 숙명여자대학교산학협력단 Pde4d 저해제를 포함하는 돌연변이 암의 치료용 조성물
RU2704613C2 (ru) * 2014-11-11 2019-10-30 Д-Р Редди'С Лабораторис Лимитед Фармацевтические препараты с фиксированной комбинацией доз обезболивающего и антиспазматического агентов
WO2017089347A1 (en) * 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
EP3383363B1 (en) * 2015-11-30 2021-01-06 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions
CN107007594A (zh) * 2017-05-08 2017-08-04 中山大学肿瘤防治中心 维生素c和奥沙利铂联用在抗肿瘤中的作用
CN108283620A (zh) * 2018-03-13 2018-07-17 兆科药业（广州）有限公司 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法

Also Published As

Publication number Publication date
WO2021213455A1 (zh) 2021-10-28
EP4140480A1 (en) 2023-03-01
EP4140480A4 (en) 2024-06-12
US20230338345A1 (en) 2023-10-26

Similar Documents

Publication Publication Date Title
TWI607754B (zh) 醫藥組合
RU2764116C2 (ru) Комбинация, содержащая палбоциклиб и 6-(2,4-дихлорфенил)-5-[4-[(3s)-1-(3-фторпропил)пиррролидин-3-ил]-8,9-дигидро-7h-бензо[7]аннулен-2-карбоновую кислоту, и ее применение для лечения рака
KR101677790B1 (ko) 키나제 저해 작용을 갖는 화합물의 병용에 의한 항종양제
EP3120851A1 (en) 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
CN101835472A (zh) N-(5-叔丁基-异噁唑-3-基)-N′-{4-[7-(2-吗啉-4-基-乙氧基)咪唑并[2,1-b][1,3]苯并噻唑-2-基]苯基}脲治疗增殖性疾病的给药方法
KR20180030630A (ko) 아필리모드를 이용한 암 치료 방법
CA3170137A1 (en) Method for treating coronavirus infections
TW201138764A (en) Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents
WO2016046786A1 (en) Long acting pharmaceutical compositions
KR20210013155A (ko) 종양 질환 치료용 약제의 제조에서 egfr 억제제와 조합된 cdk4/6 억제제의 용도
CN115397411A (zh) 药物组合及其用途
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
KR20170036010A (ko) 조합 요법
CN104688732A (zh) 利用sns-595治疗具有降低的brca2活性的癌症对象的方法
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
EP3880207B1 (en) Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof
KR20040106422A (ko) 간암 및 다른 암 질병 치료용 에포틸론 유도체
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
WO2021197333A1 (zh) 药物组合及其用途
JP2011529930A (ja) 注射可能タキサン医薬品組成物
JP2022515171A (ja) ６，８－ビス－ベンジルチオ－オクタン酸および自食作用阻害剤を使用して癌を治療するための治療方法および組成物
US20230181524A1 (en) Pharmaceutical combination and use thereof
CN115887664A (zh) 具有抗大肠癌效果的药物组合及其应用
CA3227813A1 (en) Pharmaceutical composition for treating solid tumors
CN116406275A (zh) Dhodh抑制剂化合物在组合癌症疗法中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination